Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

被引：70

作者：

Schweighofer, Carmen D. ^{[1
]}

Ritgen, Matthias ^{[2
]}

Eichhorst, Barbara F. ^{[1
]}

Busch, Raymonde ^{[3
]}

Abenhardt, Wolfgang ^{[4
]}

Kneba, Michael ^{[2
]}

Hallek, Michael ^{[1
]}

Wendtner, Clemens-Martin ^{[1
]}

机构：

[1] Univ Cologne, Innere Med Klin 1, Dept Internal Med 1, D-50937 Cologne, Germany

[2] Univ Schleswig Holstein, Med Clin 2, Kiel, Germany

[3] Tech Univ Munich, Inst Med Stat & Epidemiol, Munich, Germany

[4] Elisenhof, MOP, Munich, Germany

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2009年 / 144卷 / 01期

关键词：

chronic lymphocytic leukaemia; consolidation; antibody therapy; minimal residual disease; clinical trials; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; MINIMAL RESIDUAL DISEASE; QUANTITATIVE PCR; THERAPY;

D O I：

10.1111/j.1365-2141.2008.07394.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Alemtuzumab has shown considerable activity in untreated and relapsed chronic lymphocytic leukaemia. We report our long-term experience in 21 patients within a randomized phase III trial investigating the role of alemtuzumab for consolidation therapy after first-line fludarabine +/- cyclophosphamide, which was stopped prematurely due to severe infections. However, after a median follow-up of 48 months, progression free survival was significantly prolonged for patients receiving alemtuzumab consolidation compared to those with no further treatment (P = 0.004). Minimal residual disease (MRD) levels were persistently reduced after consolidation. Therefore, despite toxicity, MRD reduction by alemtuzumab consolidation translates into a significantly improved long-term clinical outcome.

引用

页码：95 / 98

页数：4

共 12 条

[1] Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR [J].

Brüggemann, M ;

Droese, J ;

Bolz, I ;

Lüth, P ;

Pott, C ;

von Neuhoff, N ;

Scheuering, U ;

Kneba, M .

LEUKEMIA, 2000, 14 (08) :1419-1425

[2] Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial [J].

Catovsky, D. ;

Richards, S. ;

Matutes, E. ;

Oscier, D. ;

Dyer, M. J. S. ;

FBezares, R. ;

Pettitt, A. R. ;

Hamblin, T. ;

Milligan, D. W. ;

Child, J. A. ;

Hamilton, M. S. ;

Dearden, C. E. ;

Smith, A. G. ;

Bosanquet, A. G. ;

Davis, Z. ;

Brito-Babapulle, V. ;

Else, M. ;

Wade, R. ;

Hillmen, P. .

LANCET, 2007, 370 (9583) :230-239

[3] National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].

Cheson, BD ;

Bennett, JM ;

Grever, M ;

Kay, N ;

Keating, MJ ;

OBrien, S ;

Rai, KR .

BLOOD, 1996, 87 (12) :4990-4997

[4] Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia [J].

Eichhorst, BF ;

Busch, R ;

Hopfinger, G ;

Pasold, R ;

Hensel, M ;

Steinbrecher, C ;

Siehl, S ;

Jäger, U ;

Bergmann, M ;

Stilgenbauer, S ;

Schweighofer, C ;

Wendtner, CM ;

Döhner, H ;

Brittinger, G ;

Emmerich, B ;

Hallek, M .

BLOOD, 2006, 107 (03) :885-891

[5] Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma [J].

Hainsworth, John D. ;

Vazquez, Elizabeth R. ;

Spigel, David R. ;

Raefsky, Eric ;

Bearden, James D. ;

Saez, Ruben A. ;

Greco, F. Anthony .

CANCER, 2008, 112 (06) :1288-1295

[6] Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients [J].

Leporrier, M ;

Chevret, S ;

Cazin, B ;

Boudjerra, N ;

Feugier, P ;

Desablens, B ;

Rapp, MJ ;

Jaubert, J ;

Autrand, C ;

Divine, M ;

Dreyfus, B ;

Maloum, K ;

Travade, P ;

Dighiero, G ;

Binet, JL ;

Chastang, C .

BLOOD, 2001, 98 (08) :2319-2325

[7] Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: Interim safety analysis of the CALGB study 10101 [J].

Lin, Thomas S. ;

Donohue, Kathleen A. ;

Lucas, Margaret S. ;

Byrd, John C. ;

Bengtson, Elizabeth M. ;

Peterson, Bercedis L. ;

Larson, Richard A. .

BLOOD, 2007, 110 (11) :232A-233A

[8] Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia [J].

Montillo, M ;

Tedeschi, A ;

Miqueleiz, S ;

Veronese, S ;

Cairoli, R ;

Intropido, L ;

Ricci, F ;

Colosimo, A ;

Scarpati, B ;

Montagna, M ;

Nichelatti, M ;

Regazzi, M ;

Morra, E .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2337-2342

[9] Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia [J].

O'Brien, SM ;

Kantarjian, HM ;

Thomas, DA ;

Cortes, J ;

Giles, FJ ;

Wierda, WG ;

Koller, CA ;

Ferrajoli, A ;

Browning, M ;

Lerner, S ;

Albitar, M ;

Keating, MJ .

CANCER, 2003, 98 (12) :2657-2663

[10] Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. [J].

Rai, KR ;

Peterson, BL ;

Appelbaum, FR ;

Kolitz, J ;

Elias, L ;

Shepherd, L ;

Hines, J ;

Threatte, GA ;

Larson, RA ;

Cheson, BD ;

Schiffer, CA .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (24) :1750-1757

← 1 2 →